NEW YORK (GenomeWeb News) – CombiMatrix said today that Pathology has chosen it to serve as the exclusive provider of Pathology's chromosomal microarray tests for the products of conception testing market in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.